Voting Results together with Scrutinizer Report for 37th AGM of the Company held on 27th September, 2025 at 03.00 P.M
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs Limited held its 37th Annual General Meeting on September 27, 2025 via video conferencing. All 6 resolutions were approved with near-unanimous support (~99.99% in favor) out of 40,74,604 total votes polled. Key items included adoption of FY25 audited financial statements, re-appointment of Mr. Mukund Kakani as Director (retiring by rotation), appointment of Mrs. Shilpa Bung as Independent Director for a 5-year term ending May 28, 2030, ratification of Rs. 40,000 remuneration for Bharathula & Associates as Cost Auditor for FY26, and appointment of VSS & Associates as Secretarial Auditor for FY26–FY30. The company also received approval to double its authorised share capital from Rs. 10 crore (1 crore equity shares) to Rs. 20 crore (2 crore equity shares). Only 8 promoters and 38 public shareholders attended via VC out of 7,893 shareholders on record date.
Routine, uncontested AGM with all items passing by overwhelming majority — no negative signals for shareholders. The authorised capital increase gives the board room for potential future fundraising, bonus issues, or stock splits, though no immediate dilution is implied. Investors should watch for follow-up announcements on capital actions.